Exploring a Novel Dual PARP-HDAC Inhibitor for the Treatment of Ewing Sarcoma

Time: 9:00 am
day: Day One


  • kt-3000 series compounds exhibit dual PARP1/2 and HDAC inhibitor activity
  • Co-inhibition of PARP1/2 and HDACs amplifies DNA damage and cytotoxicity
  • Ewing sarcoma cells are highly sensitive to combined PARP and HDAC inhibition